The London Stock Exchange uses cookies to improve its website. The cookies for analytical purposes have already been set. For more details and how to manage cookies, please see our privacy and cookies policy.

AZN ASTRAZENECA PLC ORD SHS $0.25




 Page 1 of 5

| 1 | 2 | 3 | 4 | 5 | Next

Time/Date Code Headline Source Impact
09:00 27-Jul-2016 AZN Notice of Results RNS -
14:15 19-Jul-2016 AZN QTERN (saxa/dapa) EU approved for type-2 diabetes RNS +1.91% Up
07:00 18-Jul-2016 AZN TAGRISSO MET PRIMARY ENDPOINT IN PHASE III TRIAL RNS +1.21% Up
12:07 14-Jul-2016 AZN Second Price Monitoring Extn RNS -0.39% Down
12:02 14-Jul-2016 AZN Price Monitoring Extension RNS -0.39% Down
07:00 13-Jul-2016 AZN AZ resolves Faslodex patent litigation in the US RNS -0.97% Down
17:30 01-Jul-2016 AZN Total Voting Rights RNS +6.57% Up
07:00 01-Jul-2016 AZN AZ enters licensing agreements with LEO Pharma RNS +6.57% Up
07:00 28-Jun-2016 AZN Zavicefta approved in EU RNS +11.52% Up
07:00 23-Jun-2016 AZN AstraZeneca updates on Flumist vaccine in the US RNS +7.80% Up
15:00 14-Jun-2016 AZN Director/PDMR Shareholding RNS -3.44% Down
07:03 09-Jun-2016 AZN AZ agreement with Aspen for anaesthetics portfolio RNS -5.04% Down
07:00 03-Jun-2016 AZN AZ completes US licensing agreement with Ironwood RNS +0.05% Up
07:00 02-Jun-2016 AZN AZ LICENSES ZURAMPIC TO GRÜNENTHAL GMBH RNS +0.69% Up
12:00 01-Jun-2016 AZN Block listing Interim Review RNS +0.61% Up
11:30 01-Jun-2016 AZN Total Voting Rights RNS +0.61% Up
12:36 27-May-2016 AZN POSITIVE CHMP OPINION IN EU FOR SAXA/DAPA RNS +1.80% Up
07:03 27-May-2016 AZN Positive results from AstraZeneca Faslodex trial RNS +1.80% Up
07:00 27-May-2016 AZN AstraZeneca receives CRL from US FDA for ZS-9 RNS +1.80% Up
16:00 23-May-2016 AZN Director/PDMR Shareholding RNS +2.34% Up

 Page 1 of 5

| 1 | 2 | 3 | 4 | 5 | Next



Price changes are calculated on the basis of the following formula: [ avg(x) - avg(y)] / avg(y) where:
x = instrument's 7 closing prices after the news has been released
y = instrument's latest 7 closing prices before the news was released, including the day of the release of the news

Please note that the news releases are only one of the multiple factors that could have had an impact on the change in the security’s price over the time period analysed by the News Analysis tool. Where data are insufficient the graph does not show any price change and the table below the graph displays a blank “ - “ next to the line indicating the RNS issue.





Company Information
Updated Monthly
Company address Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, United Kingdom
Company website http://www.astrazeneca....
Market cap(in millions)* £ 58,535.48
Listing/Admission to trading 01 Jun 1993
Trading service SETS
Market Main Market
Listing category Premium Equity Commercial Companies
*The market capitalisation of companies reflects the London listed element only. These figures are approximate and are updated monthly.

Trading Information
27-Jul-16
FTSE index FTSE All-Share,FTSE Eurotop 300,FTSE 350 High Yield,FTSE 100,FTSE 350 (ex IT),FTSE techMARK All-Share,FTSE All-Share (ex IT),FTSE 350
FTSE sector Pharmaceuticals & Biotechnology
FTSE sub-sector Pharmaceuticals
Country of share register GB
Segment SET0
MiFID Status Regulated Market
Exchange market size 500
SEDOL 0989529
ISIN number GB0009895292



ASTRAZENECA share news analysis (AZN)